Health

Doctors at NMC Royal Hospital Sharjah Restore Vision of 65-Year-Old Man After Sudden Blindness Scare

Sharjah, UAE – What began as a frightening medical emergency for a 65-year-old engineer ended with a remarkable recovery, thanks to the rapid diagnosis and coordinated care of specialists at NMC Royal Hospital Sharjah, who were able to restore his sight after he suddenly lost vision in one eye.

The patient arrived at the hospital in distress after experiencing an abrupt loss of vision in his right eye. Concerned that the condition could be related to a stroke or a neurological disorder, the medical team immediately initiated urgent investigations.

He was first evaluated by Dr. Sherif Mohamed Hussien, Neurologist, who ordered an emergency CT scan to determine the underlying cause of the sudden vision loss. While the patient feared a neurological emergency, the scan revealed an unexpected and potentially dangerous condition, a severe sinus infection.

Recognising the urgency of the situation, the patient was promptly referred to Dr. Ricardo Persaud (FRCS), Consultant ENT Surgeon, for further evaluation. During the clinical assessment, doctors observed that although the patient’s eye reflexes remained normal, there was a subtle bulging of the right eye, which raised further concern.

A detailed nasal examination uncovered the root of the problem: large nasal polyps, non-cancerous growths inside the nasal passages, along with a fungal sinus infection that was predominantly affecting the right side. Further analysis revealed that the infected sinuses were located extremely close to the eye and the optic nerve, the critical nerve responsible for transmitting visual signals to the brain.

The inflammation and pressure caused by the infection had begun to compress the optic nerve, leading to the sudden loss of vision.

Emergency Surgery to Protect the Optic Nerve

Given the high risk of permanent vision loss, the medical team decided to proceed with urgent surgical intervention.

The patient underwent Functional Endoscopic Sinus Surgery (FESS), a minimally invasive procedure that allows surgeons to access and treat sinus disease through the nasal passages using a small endoscopic camera. During the procedure, surgeons carefully removed the infected tissue and cleared the obstructed sinus cavities.

While operating, doctors discovered that part of the thin bone separating the sinuses from the eye had already been partially eroded due to the infection, a sign of how advanced the condition had become. Fortunately, the infection had not yet spread directly into the eye, allowing the surgical team to relieve the pressure before irreversible damage occurred.

A Rapid and Remarkable Recovery

The patient began noticing improvement in his vision shortly after the surgery.

At his one-week follow-up appointment, nearly 80 percent of his vision had returned. Over the following weeks, his recovery continued steadily. By the four-week mark, his eyesight had been fully restored, and his sense of smell, which had also been affected by the sinus disease, had returned as well.

A Warning About Hidden Sinus Complications

Although sinus infections and nasal polyps are often considered routine conditions, this case highlights that in rare circumstances they can lead to serious and unexpected complications, including vision loss if left untreated.

Specialists at NMC Royal Hospital Sharjah emphasise that persistent sinus symptoms such as nasal blockage, facial pressure, headaches or changes in vision should never be ignored. Early diagnosis through proper medical evaluation and imaging can prevent complications and protect vital functions like eyesight.

The multidisciplinary team expressed satisfaction with the successful outcome, noting that the case demonstrates the importance of rapid diagnosis, collaboration between specialties, and timely surgical intervention.

The patient, who described the experience as deeply frightening, expressed heartfelt gratitude to the doctors, nurses and medical staff at NMC Royal Hospital Sharjah for their swift action and compassionate care.

“I was terrified when I suddenly lost my sight,” he said. “But the doctors acted quickly and explained everything clearly. Thanks to them, I can see again and I’m incredibly grateful.”

Health

PCOS: Matter Of Eggs And Far Beyond

Dr. Pooja Vaswani – Consultant Obstetrics & Gynaecology.

NMC Royal Hospital, Abu Dhabi

Quite many times in our daily practice we come across women who are diagnosed to have Polycystic Ovarian Syndrome (PCOS), the incidence of which is on an increase. It affects about 10% of women. It’s the word “PCOS” that catches any woman’s attention, as more often than not she would have heard about PCOS from her friends/ mother or sisters. Immediate question that comes to the mind of the woman is “will I be able to conceive?”

Ofcourse maternal instinct is paramount and being a gynecologist women with PCOS come to me with concerns that are either cosmetic or reproductive. As gynecologist we cater to reproductive goal,however it is to be kept in mind that as a doctor our role does not end there. PCOS has long term implications too which can go far beyond the reproductive age.Many studies confirm that the insulin resistance associated with PCOS can expose women to higher risk of metabolic syndrome which could be a combination of hypertension; hyperlipidemia, diabetes and cardiovascular disease.

Apart from these metabolic disorders, women with PCOS are also at an increased risk of developing endometrial, ovarian and possibly also breast cancer in later life.

There is a need for a holistic approach in dealing with PCOS keeping in mind that contrary to what the name implies, PCOS implications are not restricted just to sex organs but go way beyond, affecting many other organs in the body which can have profound effect on long term health of the women. These women should be evaluated for these conditions accordingly on a more frequent basis.

Every responsible gynecologist should utilize every potential opportunity to evaluate and educate the patients about ways to prevent these potentially threatening long term metabolic and malignant disorders by intervening at the earliest.

Health

Novartis: Rare muscle disease drug shows early promise

Novartis (NOVN.S), opens new tab said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of ‌Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.

The Swiss ⁠drugmaker said the drug, known as del-brax, lowered two blood markers linked to the disease and showed reduced signs of muscle damage in patients with facioscapulohumeral muscular dystrophy.
Novartis said the drug shows potential to become the first disease-modifying ‌treatment ⁠for FSHD, which can cause weakness in the face, shoulders, arms and other muscles.
The company estimates it affects about 45,000 to ⁠87,000 people in the U.S. and EU.
The drug’s safety profile was consistent with previous ⁠results, the company said.
Novartis plans to discuss the data with health regulators ⁠around the world, while a late-stage study of the drug is currently enrolling patients.

The Thomson Reuters

Health

Obesity drug shows promise in reducing belly and liver fat

Boehringer Ingelheim said on Sunday its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in ‌a late-stage study, data showed, bolstering its case for benefits beyond weight loss as competition in obesity drugs intensifies.

The drug, survodutide, was licensed from Denmark’s Zealand Pharma (ZELA.CO), opens new tab. An injectable that mimics the proteins GLP-1 and glucagon to create a feeling of fullness, its weight-loss trial results were announced in April, showing patients lost an average of 16.6% over 76 weeks.

Analysis of a group of patients who had MRI measurements at the start and end of a 76-week trial showed that survodutide reduced harmful ⁠abdominal fat by up to 34% and liver fat by up to 63.1% from the baseline, Boehringer said.

Analysts have said the weight-loss numbers were broadly comparable to existing GLP-1 injections from Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab and below newer rivals in development, and that the company needed to differentiate the drug’s benefits.

Lean mass accounted for no more than 10.8% of the change in body composition at the highest dose of 6 milligrams, suggesting the weight loss was driven mainly by fat reduction.

The drug’s effect on liver-fat reduction and preservation of lean mass are central to whether it will be able to stand out commercially, alongside tolerability and how long patients stay on the drug. Detailed data from the study could help Boehringer make a ‌stronger case ⁠that survodutide should be judged not only by pounds lost but by where weight is lost.

“We believe survodutide will become an important new option at the intersection of obesity and liver disease, two conditions that are deeply connected but rarely addressed together,” said Boehringer executive Shashank Deshpande, who leads the company’s human medicines business.

Boehringer acquired the rights in 2011 to solely develop and commercialise survodutide from Zealand, which is ⁠entitled to royalty payments on global revenue.

PATIENTS WITH LIVER DISEASE BENEFIT

In a separate late-stage study of overweight or obese patients with a fatty liver disease called MASLD, survodutide met both its main goals.

After 48 weeks, up to 84.2% of patients on the drug showed ⁠a liver fat reduction of at least 30%, compared with 24.3% for those on placebo. Patients on survodutide also lost up to 12.2% of their body weight, versus 1% for placebo.

In 61% of the patients the drug helped achieve liver fat ⁠normalization, or a liver fat content below 5%, compared with 5.7% on placebo.

U.S. biotech Altimmune (ALT.O), opens new tab is also developing a drug that targets both the appetite-suppressing gut hormone, GLP-1, and glucagon.

Survodutide is also being tested in other late-stage studies, including for patients with fatty liver disease and fibrosis.

REUTERS